COMBINED SYNOPSIS / SOLICITATION

1. Action Code:  Combined Synopsis/Solicitation
    
2. Date: March 16, 2020
    
3. Year: 2020
    
4. Contracting Office Zip Code: 20892
    
5. Classification Code:
    
6. Contracting Office Address:
   6710B Rockledge Drive
   Bethesda, MD 20892
    
7. Subject/Title: U-Plex Assay Kits
    
8. Proposed Solicitation Number: NICHD-20-063-RV-1
    
9. Closing Response Date: March 31, 2020
    
10. Contact Point: Verne L Griffin
     
11. Contract Award and Solicitation Number: TBD
     
12. Contract Award Dollar Amount: TBD
     
13. Contract Line Item Number(s): TBD
     
14. Contractor Award Date: TBD
     
15. Contractor Name: TBD

1. Description: (Background)
    
    

1. “This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice.  This announcement constitutes the only solicitation; quotes are being requested and a written solicitation will not be issued.”   
    
2. The solicitation number is NICHD-20-063-RV-1 and the solicitation is issued as a request for quote (RFQ).
    
3. The solicitation document, the incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2020-04 effective 15 Jan 20
    
4. The associated NAICS code is 325414, Biological Product (except Diagnostic) Manufacturing, and the small business size standard is 1,250.  The acquisition is being conducted in accordance with the procedures of FAR Part 12 and FAR Part 13.

1. The Contractor Requirements are listed below:

Background:

The NIDDK Clinical Core Laboratory processes, labels, catalogues, stores and analyzes clinical samples for investigators within NIDDK. The Lab chose these kits to measure biomarkers for NIDDK protocol because these U-Plex kits combination of electrochemiluminescence and MULTI‑ARRAY technologies provides unsurpassed sensitivity and multiplex capabilities, making this an exceptional detection system for everything from basic research to biomarker identification to long term drug development studies, the stimulation and detection are decoupled, resulting in reduced background, and greater sensitivity, dynamic range, and data quality, it is using less volume of samples to get more accurate data with a greater dynamic range.  NIDDK’s main objective is to measure Human Gut hormones & Human Inflammatory markers U-Plex kits.

                    The contractor shall provide to brand name or equal specifications:

1: U-PLEX Metabolic Group 1 (hu) Assays, SECTOR (25 PL); Quantity: 1; Product Code: K151ACL-4

The salient characteristics and features can be found on this LINK.

1. Delivery:  The vendor shall include their delivery lead time on their quote.
    
   (viii)    The provision at FAR clause 52.212-1, Instructions to Offerors – Commercial Items, applies to this acquisition.
    
   (ix)     The provision at FAR clause 52.212-2, Evaluation – Commercial Items, is applicable.  Award will be made to the contractor providing the most advantageous quote to the government, technical factors and cost/price considered.  The technical factors are as follows: The contractor will be evaluated on their capability to provide the product to the brand name or equal specifications as stated on the solicitation. 
    

1. U-PLEX Metabolic Group 1 (hu) Assays, SECTOR (25 PL); Quantity: 1; Product Code: K151ACL-4
    
   (x)      FAR clause 52.212-3, Offeror Representations and Certifications – Commercial Items, is applicable.  An offeror shall complete only paragraphs (b) of this provision if the offeror has completed the annual representations and certificates electronically via http://www.acquisition.gov. If an offeror has not completed the annual representations and certifications electronically at the System for Award Management (SAM) website, the offeror shall complete only paragraphs (c) through (p) of this provision.
    
   (xi)     FAR clause at 52.212-4, Contract Terms and Conditions – Commercial Items, applies to this acquisition.
    
   (xii)     FAR clause at 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders – Commercial Items, applies to this acquisition.  Including the following clauses and Prohibitions:
    

1. 52.219-28, Post Award Small Business Program Representation
2. 52.222-19, Child Labor—Cooperation with Authorities and Remedies 52.222-21, Prohibition of Segregated Facilities
3. 52.222-26, Equal Opportunity
4. 52.222-36, Equal Opportunity for Workers with Disabilities
5. 52.222-50 Combating Trafficking in Persons
6. 52.225-13, Restrictions on Certain Foreign Purchases
7. 52.223-18, Encouraging Contractor Policies to Ban Text Messaging while Driving
    
   Additional Clauses:
    
8. 52.211-6 Brand Name or Equal.
    
   (xiii)    Additional Contract Requirements: None
    
   (xiv)    The Defense Priorities and Allocations System (DPAS) and assigned rating are not applicable.
    
   (xv)    Offers shall be submitted via email to  [email protected]
    

1. Place of Contract Performance:
        National Institute of Health, NIDDK
        6707 Democracy Boulevard
        II Democracy Plaza
   Bethesda, MD 20892
    
2. Set-aside Status: None